Patents by Inventor Almudena Rubio

Almudena Rubio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS INHIBITORS
    Publication number: 20240043451
    Abstract: The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.
    Type: Application
    Filed: March 24, 2023
    Publication date: February 8, 2024
    Inventors: David Anthony BARDA, Jolie Anne BASTIAN, Kelly Wayne FURNESS, Deqi GUO, James Robert HENRY, Richard Duane JOHNSTON, Jason Eric LAMAR, Tao LIU, Michael John RODRIGUEZ, Almudena RUBIO, Chong SI, Gaiying ZHAO, Mohammad Sadegh ZIA-EBRAHIMI, Matthew Patrick BAUMGARTNER, Isabel ROJO, Mario BARBERIS, Santiago CARBALLARES MARTIN, Pablo GARCIA LOSADA, Sonia Maria GUTIERREZ SANFELICIANO, Wenceslao LUMERAS AMADOR, Victoriano MOLERO FLOREZ, Maria Lourdes PRIETO VALLEJO
  • SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20230234960
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Application
    Filed: March 15, 2023
    Publication date: July 27, 2023
    Inventors: Jolie Anne BASTIAN, Jeffrey Daniel COHEN, Almudena RUBIO, Daniel Jon SALL, Jennifer Anne MCMAHON
  • Selective estrogen receptor degraders
    Patent number: 11634426
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: April 25, 2023
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Daniel Jon Sall, Jennifer Anne McMahon
  • SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20210403480
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Application
    Filed: September 2, 2021
    Publication date: December 30, 2021
    Inventors: Jolie Anne BASTIAN, Jeffrey Daniel COHEN, Almudena RUBIO, Daniel Jon SALL, Jennifer Anne MCMAHON
  • Selective estrogen receptor degraders
    Patent number: 11117902
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: September 14, 2021
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Daniel Jon Sall, Jennifer Anne McMahon
  • SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20200347073
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Application
    Filed: May 18, 2020
    Publication date: November 5, 2020
    Inventors: Jolie Anne BASTIAN, Jeffrey Daniel COHEN, Almudena RUBIO, Daniel Jon SALL
  • 1-tetrahydropyranylcarbonyl-2,3-dihydro-1H-indole compounds for treating cancer
    Patent number: 10759786
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: September 1, 2020
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
  • Selective estrogen receptor degraders
    Patent number: 10654866
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: May 19, 2020
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Daniel Jon Sall
  • SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20200017516
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Application
    Filed: July 11, 2019
    Publication date: January 16, 2020
    Inventors: Jolie Anne BASTIAN, Jeffrey Daniel COHEN, Almudena RUBIO, Daniel Jon SALL
  • 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-IH-INDOLE COMPOUNDS FOR TREATING CANCER
    Publication number: 20190161477
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Application
    Filed: May 31, 2017
    Publication date: May 30, 2019
    Inventors: Jolie Anne BASTIAN, Jiehao CHEN, Jeffrey Daniel COHEN, James Robert HENRY, William Thomas MCMILLEN, Bradley Earl REAMAN, Almudena RUBIO, Daniel Jon SALL, Gaiying ZHAO
  • Ghrelin 0-acyl transferase inhibitors
    Patent number: 10227310
    Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: March 12, 2019
    Assignee: Eli Lilly and Company
    Inventors: Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza, Almudena Rubio, Stacy Jo Keding, Daryl Lynn Smith
  • Ghrelin O-acyl transferase inhibitors
    Patent number: 10093651
    Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: October 9, 2018
    Assignee: Eli Lilly and Company
    Inventors: Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza, Almudena Rubio
  • GHRELIN 0-ACYL TRANSFERASE INHIBITORS
    Publication number: 20180086732
    Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
    Type: Application
    Filed: April 13, 2016
    Publication date: March 29, 2018
    Inventors: Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza, Almudena Rubio
  • GHRELIN 0-ACYL TRANSFERASE INHIBITORS
    Publication number: 20180079729
    Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
    Type: Application
    Filed: April 13, 2016
    Publication date: March 22, 2018
    Inventors: Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza, Almudena Rubio, Stacy Jo Keding, Daryl Lynn Smith
  • 2,3-dihydro-1H-indole compounds
    Patent number: 9872853
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: January 23, 2018
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
  • 2,3-DIHYDRO-1H-INDOLE COMPOUNDS
    Publication number: 20170354641
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Application
    Filed: May 31, 2017
    Publication date: December 14, 2017
    Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
  • Azepine derivatives as gamma-secretase inhibitors
    Patent number: 8188069
    Abstract: Compounds of formula (I), pharmaceutical compositions comprising them, and methods for their use are described.
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: May 29, 2012
    Assignee: Eli Lilly and Company
    Inventors: Melinda Joy Hope Miller, Warren Jaye Porter, Jon Kevin Reel, Almudena Rubio-Esteban
  • Thienopyridines as allosteric potentiators of the M4 muscarinic receptor
    Patent number: 8071776
    Abstract: The present invention relates to selective allosteric potentiators of the Formula (I): or pharmaceutically acceptable salts thereof, for the treatment of disorders associated with M4 muscarinic receptors.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: December 6, 2011
    Assignee: Eli Lilly and Company
    Inventors: Almudena Rubio Esteban, Darryl Wayne Hilliard
  • AZEPINE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS
    Publication number: 20100197660
    Abstract: Compounds of formula (I), pharmaceutical compositions comprising them, and methods for their use are described.
    Type: Application
    Filed: August 4, 2008
    Publication date: August 5, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Melinda Joy Hope Miller, Warren Jaye Porter, Jon Kevin Reel, Almudena Rubio-Esteban
  • THIENOPYRIDINES AS ALLOSTERIC POTENTIATORS OF THE M4 MUSCARINIC RECEPTOR
    Publication number: 20090105244
    Abstract: The present invention relates to selective allosteric potentiators of the Formula (I): or pharmaceutically acceptable salts thereof, for the treatment of disorders associated with M4 muscarinic receptors.
    Type: Application
    Filed: October 18, 2005
    Publication date: April 23, 2009
    Applicant: ELI LILLY AND COMPANY
    Inventors: Almudena Rubio Esteban, Darryl Wayne Hilliard